Birinapant
- Generic Name
- Birinapant
- Drug Type
- Small Molecule
- Chemical Formula
- C42H56F2N8O6
- CAS Number
- 1260251-31-7
- Unique Ingredient Identifier
- 6O4Z07B57R
- Background
Birinapant has been investigated for the treatment of Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML).
Dose Escalation, Combination Chemotherapy Safety Study of Birinapant (TL32711), in Subjects With Advanced or Metastatic Solid Tumors
- First Posted Date
- 2010-08-25
- Last Posted Date
- 2016-05-30
- Lead Sponsor
- TetraLogic Pharmaceuticals
- Target Recruit Count
- 176
- Registration Number
- NCT01188499
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Center, Detroit, Michigan, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸Holy Cross Hospital, Fort Lauderdale, Florida, United States
Dose Escalation Safety Study of TL32711 in Adults With Refractory Solid Tumors or Lymphoma
- First Posted Date
- 2009-10-12
- Last Posted Date
- 2016-03-03
- Lead Sponsor
- TetraLogic Pharmaceuticals
- Target Recruit Count
- 50
- Registration Number
- NCT00993239
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath